Good Example of what I shared above. Keytruda ($20.9 billion in 2022) is facing LOE i believe 2028, so they file for a new patent for the subcutaneous version of the currently infused drug.
Good Example of what I shared above. Keytruda ($20.9 billion in 2022) is facing LOE i believe 2028, so they file for a new patent for the subcutaneous version of the currently infused drug.